Vetdrugs 2.0Betamethasone is a potent, long-acting glucocorticoid used to suppress inflammation and inappropriate immune activity. Veterinary applications overlap with those of other systemic corticosteroids, but its potency and duration make direct milligram substitution inappropriate. Clinical effects depend on both the active drug and the formulation used.
Equine intra-articular products may combine a soluble phosphate component with a less soluble acetate component to provide different release characteristics. Such local treatment is distinct from an arbitrary systemic steroid regimen and does not correct the mechanical or structural causes of osteoarthritis.
Group
Glucocorticoid
Mechanism of Action
Betamethasone enters cells and binds intracellular glucocorticoid receptors. The activated receptor complex alters gene transcription, decreasing expression of multiple inflammatory mediators and modifying immune-cell activation, trafficking and function. Effects develop through changes in cellular signaling and protein production rather than simple chemical neutralization of an inflammatory substance.
Suppression of cytokine signaling and inflammatory enzyme pathways reduces vascular and cellular components of inflammation. At immunosuppressive exposure, broader inhibition of immune responses accounts for use in immune-mediated disease. The same receptor effects also alter metabolism and suppress hypothalamic–pituitary–adrenal activity.
Soluble and depot esters differ in release from the administration site, influencing onset and persistence without changing the basic glucocorticoid receptor target. Local injection can reduce inflammation in the treated area, but some systemic absorption and glucocorticoid effects may still occur.
Dose Rates
Dogs
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Anti-inflammatory treatment | 0.1–0.2 mg/kg | PO | Every 12–24 h | |
| Immunosuppression | 0.2–0.5 mg/kg | PO | Every 12–24 h |
Cats
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Anti-inflammatory treatment | 0.1–0.2 mg/kg | PO | Every 12–24 h | |
| Immunosuppression | 0.2–0.5 mg/kg | PO | Every 12–24 h |
Large animals
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Inflammatory disease | 0.05–0.1 mg/kg | IM, PO | Every 24 h | The monograph gives a general large-animal regimen without assigning individual species. |
Indications
- Treatment of selected inflammatory diseases requiring potent glucocorticoid activity.
- Immunosuppression for selected immune-mediated disorders.
- Intra-articular control of pain and inflammation associated with equine osteoarthritis using an appropriate formulation.
Contraindications
- Do not inject an infected joint.
- Use cautiously with diabetes, renal failure, pregnancy, infection, ulcer risk or impaired wound healing.
- Systemic fungal infection unless a separate essential replacement indication exists.
- Avoid long-acting injectable glucocorticoids for chronic systemic therapy.
- Avoid IM corticosteroid injection with idiopathic thrombocytopenia.
- Late-pregnancy administration can induce parturition in large animals.
Interactions
- NSAIDs increase gastrointestinal injury risk.
- Potassium-depleting diuretics can increase hypokalemia risk; insulin requirements may rise during glucocorticoid exposure.
- Amphotericin B and potassium-depleting diuretics increase hypokalemia risk; hypokalemia increases digoxin toxicity.
- Ketoconazole can increase glucocorticoid exposure; rifampin and barbiturates may reduce it.
- Live attenuated vaccines should generally be avoided during immunosuppressive glucocorticoid treatment.
- Concurrent anticholinesterase treatment in myasthenia gravis can produce marked weakness; adjust under the disease-specific plan.
Adverse effects
- Polyphagia, polyuria and polydipsia
- Adrenal suppression
- Gastrointestinal ulceration
- Hepatopathy and hyperlipidemia
- Hyperglycemia and diabetes
- Immunosuppression and secondary infection
- Delayed healing and reduced protein synthesis
Preparations
| Preparation | Form | Strength | Route |
|---|---|---|---|
| Betamethasone 0.6 mg tablet Oral availability may be limited. | Tablet | 0.6 mg / tablet | PO |
| Betamethasone 3 mg/mL injection | Injection | 3 mg / mL | IM |
| Betamethasone oral solution 0.6 mg/5 mL | Oral Liquid | 0.6 mg / 5 mL | PO |
Monitoring and Administration
Monitor CBC and adrenal function during systemic treatment.
The equine intra-articular suspension combines rapid and prolonged release components. Administer 1.5 mL per joint (9 mg total betamethasone equivalents); intra-articular administration is not represented by the calculator route set.
Protect from light at room temperature. Open equine single-use vials once and discard the remainder.
An additional equine intra-articular alternative is 6–15 mg per joint; repeat only as necessary to maintain the clinical response. It is distinct from the fixed 9 mg-per-joint product regimen.
A historical canine pruritus regimen used Betasone aqueous suspension 0.25–0.5 mL per 20 lb IM, with no more than four injections. Product-specific composition and prolonged release must be retained; do not substitute a soluble injection.
Taper prolonged systemic therapy to allow adrenal recovery. Stress during or after tapering may require temporary glucocorticoid supplementation. Monitor glucose, weight, albumin, electrolytes and growth in young animals.